Global Diagnostic Tests Market - Industry Trends and Forecast to 2027

Global diagnostic tests market is projected to register a CAGR of 9.0% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027

Market Segmentation:

Global Diagnostic Tests Market, By Type (Glucose Test, Infectious Diseases Test, Cytology Test, CBC Test, Blood Culture Test, Syphilis Test, Urea Test, C-Reactive Protein Test, Antigen Test, HBA1C Test, Pregnancy Test, Lipid Profile Test, Electrolytes Test, Liver Function Test, Stool Helicobacter Pylori Test, Calcium Test, Crossmatch Test, Thyroid Function Test, Stool Microscopy Test, Urine Microscopy Test, Unit Packed RBCS Test, ESR Test and Others Test), Solution (Services and Products), Technology (Immunoassay-Based, PCR-Based, Next Gene Sequencing, Spectroscopy-Based, Chromatography-Based, Microfluidics, Substrate Technology and Others), Mode of Testing (Prescription Based Testing, OTC Testing), Approach (Molecular Diagnostic Instrument, In-Vitro Diagnostic Instrument & Point of Care Testing Instrument), Sample Type (Urine, Saliva, Blood, Hair, Sweat, and Others), Application (Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, Odontology and Others), Testing Type (Biochemistry, Hematology, Microbiology, Histopathology and Others), Age (Pediatric, Adult & Geriatric), End User (Hospitals, Diagnostic Center, Research Labs and Institutes, Research Institute, Homecare, Blood Banks, Specialty Clinics, Ambulatory Surgical Centers (ASCs), Others), Distribution Channel (Direct Tenders, Retail Sales, Online Sales), Country (U.S., Canada & Mexico, Japan, Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland & Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, & Rest of Asia-Pacific, Brazil, Argentina & Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel & rest of Middle East and Africa) Industry trends and forecast 2027

Some of the major factors contributing to the growth of the global diagnostic tests market are:

Increasing prevalence of chronic diseases

Rising number of IVD tests conducted across the globe

Adequate Reimbursement policies

Market Players

The key market players for global diagnostic tests market are listed below:

F. Hoffmann-La Roche Ltd

Abbott

Danaher

Siemens Healthcare GmbH

bioMerieux SA

Thermo Fisher Scientific Inc.

WerfenLife, S.A.

Bio-Rad Laboratories, Inc

Sysmex Corporation

PerkinElmer Inc

QIAGEN

Illumina, Inc

Ortho Clinical Diagnostics

Quidel Corporation

BD

ARKRAY

DiaSorin Inc

Grifols, S.A.

Sannuo biosensor Ltd

Nova Biomedical

STRECK

BODITECH MED INC

EKF DIAGNOSTICS HOLDINGS PLC

Chembio Diagnostic Systems, Inc.

Medixbiochemica

NanoEnTek Inc

ACON Laboratories, Inc

Hemosure, Inc

Biohit Oyj

Germaine Laboratories, Inc

HUMASIS

LifeSign LLC

LamdaGen Corporation

BIOMEDOMICS INC

MicroGen Diagnostics

TABLE OF CONTENTS

TABLE OF CONTENTS

1 INTRODUCTION 83

• 1.1 OBJECTIVES OF THE STUDY 83
• 1.2 MARKET DEFINITION 83
• 1.3 OVERVIEW OF GLOBAL DIAGNOSTIC TESTS MARKET 84
• 1.4 CURRENCY AND PRICING 86
• 1.5 LIMITATIONS 87
• 1.6 MARKETS COVERED 87

2 MARKET SEGMENTATION 95

• 2.1 MARKETS COVERED 95
• 2.2 GEOGRAPHICAL SCOPE 97
• 2.3 YEARS CONSIDERED FOR THE STUDY 98
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 99
• 2.5 MULTIVARIATE MODELLING 102
• 2.6 LIFELINE CURVE BY TYPE 102
• 2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 103
• 2.8 DBMR MARKET POSITION GRID 104
• 2.9 VENDOR SHARE ANALYSIS 105
• 2.10 SECONDARY SOURCES 106
• 2.11 ASSUMPTIONS 106

3 EXECUTIVE SUMMARY 107

4 PREMIUM INSIGHTS 110

5 MARKET OVERVIEW 111

• 5.1 DRIVERS 113
  • 5.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 113
  • 5.1.2 RISING NUMBER OF IVD TESTS CONDUCTED ACROSS THE GLOBE 114
  • 5.1.3 ADEQUATE REIMBURSEMENT POLICIES 115
  • 5.1.4 IMPROVING DIAGNOSIS SEEKING RATE ACROSS THE GLOBE 116
  • 5.1.5 EXTENDING REACH OF MOLECULAR DIAGNOSTICS 117
• 5.2 RESTRAINTS 118
  • 5.2.1 HIGH COST OF KITS 118
  • 5.2.2 NON-AVAILABILITY OF RELEVANT AND UNAPPROPRIATED KITS 119
  • 5.2.3 LACK OF TRAINED LABORATORY MANPOWER 119
• 5.3 OPPORTUNITIES 120
  • 5.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 120
  • 5.3.2 EXPANDING BUSINESS THROUGH SUBSIDIARIES 121
  • 5.3.3 RISING AWARENESS AND GOVERNMENT FUNDING 123
• 5.4 CHALLENGES 124
  • 5.4.1 STRINGENT RULES & REGULATIONS 124
  • 5.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 124

6 IMPACT OF COVID-19 ON GLOBAL DIAGNOSTIC TESTS MARKET 125

• 6.1 STRATEGIC INITIATIVES BY THE PLAYERS 125
• 6.2 IMPACT ON DEMAND OF IN VITRO DIAGNOSTICS 125
• 6.3 INCREASE IN THE PRICE OF TESTS KITS & REAGENTS 126

7 GLOBAL DIAGNOSTIC TESTS MARKET, BY TYPE 127

• 7.1 OVERVIEW 128
• 7.2 GLUCOSE TEST 133
• 7.3 INFECTIOUS DISEASES TEST 133
• 7.4 CYTOLOGY TEST 134
• 7.5 CBC TEST 135
• 7.6 BLOOD CULTURE TEST 136
• 7.7 SYPHILIS TEST 136
• 7.8 UREA TEST 137
• 7.9 C-REACTIVE PROTEIN TEST 138
• 7.10 ANTIGEN TEST 138
• 7.11 HBA1C TEST 139
• 7.12 PREGNANCY TEST 140
• 7.13 LIPID PROFILE TEST 140
• 7.14 ELECTROLYTES TEST 141
• 7.15 LIVER FUNCTION TEST 142
• 7.16 STOOL HELICOBACTER PYLORI TEST 142
• 7.17 CALCIUM TEST 143
• 7.18 CROSSMATCH TEST 144
• 7.19 THYROID FUNCTION TEST 144
• 7.20 STOOL MICROSCOPY TEST 145
• 7.21 URINE MICROSCOPY TEST 145
• 7.22 UNIT PACKED RBCS TEST 146
• 7.23 ESR TEST 147
• 7.24 OTHERS TEST 148

8 GLOBAL DIAGNOSTIC TESTS MARKET, BY SOLUTION 149

• 8.1 OVERVIEW 150
• 8.2 SERVICES 153
• 8.3 PRODUCTS 153
  • 8.3.1 INSTRUMENTS 154
    • 8.3.1.1 DIAGNOSTIC TYPE 154
      • 8.3.1.1.1 IN-VITRO DIAGNOSTIC INSTRUMENT 154
      • 8.3.1.1.2 POINT OF CARE TESTING INSTRUMENT 154
      • 8.3.1.1.3 MOLECULAR DIAGNOSTIC INSTRUMENT 154
    • 8.3.1.2 TYPE 155
      • 8.3.1.2.1 ANALYZER 155
      • 8.3.1.2.2 PCR BASED DEVICE 155
      • 8.3.1.2.3 SEQUENCING DEVICE 155
      • 8.3.1.2.4 PLATE READER 155
      • 8.3.1.2.5 CELL COUNTER 156
      • 8.3.1.2.6 CENTRIFUGATION DEVICE 157
      • 8.3.1.2.7 COUGULATION DEVICES 157
      • 8.3.1.2.8 BLOOD COLLECTION DEVICE 157
      • 8.3.1.2.9 SPECTOMETER 157
      • 8.3.1.2.10 FLUROSCENCE DEVICE 157
      • 8.3.1.2.11 AUTOCLAVE 157
      • 8.3.1.2.12 OTHERS 157
  • 8.3.2 REAGENTS 158
    • 8.3.2.1 GLUCOSE MONITORING KITS 158
    • 8.3.2.2 URINALYSIS TESTING KITS 158
    • 8.3.2.3 INFECTIOUS DISEASE TESTING KITS 158
    • 8.3.2.4 INSTANT SALIVA TEST KITS 158
    • 8.3.2.5 PREGNANCY TESTING KITS 158
    • 8.3.2.6 CARDIAC ASSAYS 159
    • 8.3.2.7 SPRAY/SWEAT DRUG TEST KITS 159
    • 8.3.2.8 OTHERS 159
  • 8.3.3 CONSUMABLES 159
    • 8.3.3.1 NEEDLES AND SYRINGES 159
    • 8.3.3.2 MEDIA CULTURE 159
      • 8.3.3.2.1 BROTH 160
      • 8.3.3.2.2 AGAR 160
      • 8.3.3.2.3 OTHERS 160
    • 8.3.3.3 STAINS 160
      • 8.3.3.3.1 GRAM STAINS 160
      • 8.3.3.3.2 MYCOBACTERIA STAINS 161
      • 8.3.3.3.3 FUNGAL STAINS 161
      • 8.3.3.3.4 OTHERS 161
    • 8.3.3.4 CONTROLS & CALIBRATORS 161
    • 8.3.3.5 PLATES 161
    • 8.3.3.6 OTHERS 161

9 GLOBAL DIAGNOSTIC TESTS MARKET, BY TECHNOLOGY 162

• 9.1 OVERVIEW 163
• 9.2 IMMUNOASSAY-BASED 166
  • 9.2.1 SANDWICH ASSAYS 167
  • 9.2.2 COMPETITIVE ASSAYS 167
• 9.3 PCR-BASED 167
• 9.4 NEXT GENE SEQUENCING 168
• 9.5 SPECTROSCOPY-BASED 168
  • 9.5.1 OPTICAL SPECTROSCOPY 169
  • 9.5.2 MASS SPECTROMETRY 169
  • 9.5.3 RAMAN SPECTROSCOPY 170
  • 9.5.4 OTHERS 170
• 9.6 CHROMATOGRAPHY-BASED 170
  • 9.6.1 LC-MS/MS 171
  • 9.6.2 LC-MS 171
  • 9.6.3 GC-MS 171
• 9.7 MICROFLUIDICS 171
  • 9.7.1 PAPER-BASED MICROFLUDICS 172
  • 9.7.2 LUCIFERASE IMMUNOPRECIPITATION SYSTEMS (LIPS) 172
  • 9.7.3 OTHERS 172
• 9.8 SUBSTRATE TECHNOLOGY 173
• 9.9 OTHERS 173

10 GLOBAL DIAGNOSTIC TESTS MARKET, BY MODE OF TESTING 174

• 10.1 OVERVIEW 175
• 10.2 PRESCRIPTION-BASED TESTING 178
• 10.3 OTC TESTING 178

11 GLOBAL DIAGNOSTIC TESTS MARKET, BY APPROACH 180

• 11.1 OVERVIEW 181
• 11.2 IN-VITRO DIAGNOSTIC INSTRUMENT 184
• 11.3 POINT OF CARE TESTING INSTRUMENT 184
• 11.4 MOLECULAR DIAGNOSTIC INSTRUMENT 185

12 GLOBAL DIAGNOSTIC TESTS MARKET, BY SAMPLE TYPE 186

• 12.1 OVERVIEW 187
• 12.2 BLOOD 190
• 12.3 URINE 190
• 12.4 SALIVA 191
• 12.5 SWEAT 191
• 12.6 HAIR 192
• 12.7 OTHERS 192

13 GLOBAL DIAGNOSTIC TESTS MARKET, BY APPLICATION 194

• 13.1 OVERVIEW 195
• 13.2 CARDIOLOGY 198
  • 13.2.1 GLUCOSE TESTING 198
  • 13.2.2 URINALYSIS 198
  • 13.2.3 HEMATOLOGY 199
  • 13.2.4 HB1AC TESTING 199
  • 13.2.5 COAGULATION 199
  • 13.2.6 INFECTIOUS DISEASES TESTING 199
  • 13.2.7 CARDIAC MARKERS 199
  • 13.2.8 FECAL OCCULT TESTING 199
  • 13.2.9 BLOOD GAS/ELECTROLYTES 199
  • 13.2.10 OTHERS 199
• 13.3 ONCOLOGY 200
  • 13.3.1 TUMOR MARKER TESTS 200
  • 13.3.2 HEMATOLOGY 200
  • 13.3.3 URINALYSIS 200
  • 13.3.4 LIPID TESTING 200
  • 13.3.5 BLOOD GAS/ELECTROLYTES 201
  • 13.3.6 OTHERS 201
• 13.4 ORTHOPEDICS 201
  • 13.4.1 HEMATOLOGY 201
  • 13.4.2 URINALYSIS 202
  • 13.4.3 INFECTIOUS DISEASES TESTING 202
  • 13.4.4 OTHERS 202
• 13.5 GASTROENTROLOGY 202
  • 13.5.1 INFECTIOUS DISEASES TESTING 203
  • 13.5.2 HEMATOLOGY 203
  • 13.5.3 URINALYSIS 203
  • 13.5.4 STOOL ACIDITY TEST 203
  • 13.5.5 FECAL OCCULT TESTING 203
  • 13.5.6 OTHERS 203
• 13.6 GYNECOLOGY 203
  • 13.6.1 HEMATOLOGY 204
  • 13.6.2 URINALYSIS 204
  • 13.6.3 BLOOD GAS/ELECTROLYTES 204
  • 13.6.4 OTHERS 204
• 13.7 NEUROLOGY 204
  • 13.7.1 COAGULATION 205
  • 13.7.2 INFECTIOUS DISEASES TESTING 205
  • 13.7.3 FECAL OCCULT TESTING 205
  • 13.7.4 OTHERS 205
• 13.8 ODONTOLOGY 206
  • 13.8.1 INFECTIOUS DISEASES TESTING 206
  • 13.8.2 HEMATOLOGY 206
  • 13.8.3 URINALYSIS 206
  • 13.8.4 OTHERS 206
• 13.9 OTHERS 207

14 GLOBAL DIAGNOSTIC TESTS MARKET, BY TESTING TYPE 208

• 14.1 OVERVIEW 209
• 14.2 HEMATOLOGY 212
• 14.3 BIOCHEMISTRY 212
• 14.4 MICROBIOLOGY 213
• 14.5 HISTOPATHOLOGY 213
• 14.6 OTHERS 214

15 GLOBAL DIAGNOSTIC TESTS MARKET, BY AGE 215

• 15.1 OVERVIEW 216
• 15.2 GERIATRIC 219
• 15.3 ADULT 219
• 15.4 PEDIATRIC 220

16 GLOBAL DIAGNOSTIC TESTS MARKET, BY END USER 221

• 16.1 OVERVIEW 222
• 16.2 HOSPITALS 225
• 16.3 DIAGNOSTIC CENTER 225
• 16.4 AMBULATORY SURGICAL CENTERS (ASCS) 226
• 16.5 SPECIALTY CLINICS 226
• 16.6 HOMECARE 227
• 16.7 BLOOD BANKS 228
• 16.8 RESEARCH LABS & INSTITUTES 229
• 16.9 OTHERS 229

17 GLOBAL DIAGNOSTIC TESTS MARKET, BY DISTRIBUTION CHANNEL 231

• 17.1 OVERVIEW 232
• 17.2 DIRECT TENDER 235
• 17.3 RETAIL SALES 235
• 17.4 ONLINE SALES 236

18 GLOBAL DIAGNOSTIC TESTS MARKET BY GEOGRAPHY 237

• 18.1 GLOBAL 237
• 18.2 NORTH AMERICA 241
  • 18.2.1 U.S. 257
  • 18.2.2 CANADA 268
  • 18.2.3 MEXICO 279
• 18.3 EUROPE 290
  • 18.3.1 GERMANY 306
  • 18.3.2 U.K. 317
  • 18.3.3 FRANCE 328
  • 18.3.4 ITALY 339
  • 18.3.5 SPAIN 350
  • 18.3.6 RUSSIA 361
  • 18.3.7 NETHERLANDS 372
  • 18.3.8 SWITZERLAND 383
  • 18.3.9 NORWAY 394
  • 18.3.10 POLAND 405
  • 18.3.11 TURKEY 416
  • 18.3.12 HUNGARY 427
  • 18.3.13 AUSTRIA 438
  • 18.3.14 LUTHUANIA 449
  • 18.3.15 IRELAND 460
  • 18.3.16 REST OF EUROPE 471
• 18.4 ASIA-PACIFIC 472
  • 18.4.1 CHINA 488
  • 18.4.2 JAPAN 499
  • 18.4.3 INDIA 510
  • 18.4.4 SOUTH KOREA 521
  • 18.4.5 INDONESIA 532
  • 18.4.6 AUSTRALIA 543
  • 18.4.7 THAILAND 554
  • 18.4.8 SINGAPORE 565
  • 18.4.9 MALAYSIA 576
  • 18.4.10 VIETNAM 587
  • 18.4.11 PHILIPPINES 598
  • 18.4.12 REST OF ASIA-PACIFIC 609
• 18.5 SOUTH AMERICA 610
  • 18.5.1 BRAZIL 625
  • 18.5.2 ARGENTINA 636
  • 18.5.3 PERU 647
  • 18.5.4 REST OF SOUTH AMERICA 658
• 18.6 MIDDLE EAST AND AFRICA 659
  • 18.6.1 SOUTH AFRICA 675
  • 18.6.2 UAE 686
  • 18.6.3 ISRAEL 696
  • 18.6.4 SAUDI ARABIA 707
  • 18.6.5 EGYPT 718
  • 18.6.6 KUWAIT 729
  • 18.6.7 REST OF MIDDLE EAST AND AFRICA 740

19 GLOBAL DIAGNOSTIC TESTS MARKET, COMPANY LANDSCAPE 741

• 19.1 COMPANY SHARE ANALYSIS: GLOBAL 741
• 19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 742
• 19.3 COMPANY SHARE ANALYSIS: EUROPE 743
• 19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 744

20 SWOT 745

21 COMPANY PROFILES 746

• 21.1 F. HOFFMANN-LA ROCHE LTD 746
  • 21.1.1 COMPANY SNAPSHOT 746
  • 21.1.2 REVENUE ANALYSIS 746
  • 21.1.3 COMPANY SHARE ANALYSIS 747
  • 21.1.4 PRODUCT PORTFOLIO 747
  • 21.1.5 RECENT DEVELOPMENTS 748
• 21.2 ABBOTT 749
  • 21.2.1 COMPANY SNAPSHOT 749
  • 21.2.2 REVENUE ANALYSIS 749
  • 21.2.3 COMPANY SHARE ANALYSIS 750
  • 21.2.4 PRODUCT PORTFOLIO 750
  • 21.2.5 RECENT DEVELOPMENTS 751
• 21.3 DANAHER 752
  • 21.3.1 COMPANY SNAPSHOT 752
  • 21.3.2 REVENUE ANALYSIS 752
  • 21.3.3 COMPANY SHARE ANALYSIS 753
  • 21.3.4 PRODUCT PORTFOLIO 753
  • 21.3.5 RECENT DEVELOPMENTS 754

 

• 21.4 SIEMENS HEALTHCARE GMBH 755
  • 21.4.1 COMPANY SNAPSHOT 755
  • 21.4.2 REVENUE ANALYSIS 755
  • 21.4.3 COMPANY SHARE ANALYSIS 756
  • 21.4.4 PRODUCT PORTFOLIO 756
  • 21.4.5 RECENT DEVELOPMENTS 757
• 21.5 BIOMERIEUX SA 758
  • 21.5.1 COMPANY SNAPSHOT 758
  • 21.5.2 REVENUE ANALYSIS 758
  • 21.5.3 COMPANY SHARE ANALYSIS 759
  • 21.5.4 PRODUCT PORTFOLIO 759
  • 21.5.5 RECENT DEVELOPMENTS 760
• 21.6 THERMO FISHER SCIENTIFIC INC. 761
  • 21.6.1 COMPANY SNAPSHOT 761
  • 21.6.2 REVENUE ANALYSIS 761
  • 21.6.3 PRODUCT PORTFOLIO 762
• 21.7 WERFENLIFE, S.A. 763
  • 21.7.1 COMPANY SNAPSHOT 763
  • 21.7.2 REVENUE ANALYSIS 763
  • 21.7.3 PRODUCT PORTFOLIO 764
  • 21.7.4 RECENT DEVELOPMENT 764
• 21.8 BIO-RAD LABORATORIES, INC. 765
  • 21.8.1 COMPANY SNAPSHOT 765
  • 21.8.2 REVENUE ANALYSIS 765
  • 21.8.3 PRODUCT PORTFOLIO 766
  • 21.8.4 RECENT DEVELOPMENTS 768
• 21.9 ACON LABORATORIES, INC. 769
  • 21.9.1 COMPANY SNAPSHOT 769
  • 21.9.2 PRODUCT PORTFOLIO 769
  • 21.9.3 RECENT DEVELOPMENTS 770
• 21.10 ARKRAY USA, INC. 771
  • 21.10.1 COMPANY SNAPSHOT 771
  • 21.10.2 PRODUCT PORTFOLIO 771
  • 21.10.3 RECENT DEVELOPMENTS 771
• 21.11 BD 773
  • 21.11.1 COMPANY SNAPSHOT 773
  • 21.11.2 REVENUE ANALYSIS 773
  • 21.11.3 PRODUCT PORTFOLIO 774
  • 21.11.4 RECENT DEVELOPMENT 774

 

• 21.12 BIOMEDOMICS INC. 775
  • 21.12.1 COMPANY SNAPSHOT 775
  • 21.12.2 PRODUCT PORTFOLIO 775
  • 21.12.3 RECENT DEVELOPMENT 775
• 21.13 BIOHIT OYJ 776
  • 21.13.1 COMPANY SNAPSHOT 776
  • 21.13.2 REVENUE ANALYSIS 777
  • 21.13.3 PRODUCT PORTFOLIO 777
  • 21.13.4 RECENT DEVELOPMENTS 778
• 21.14 BODITECH MED INC. 778
  • 21.14.1 COMPANY SNAPSHOT 778
  • 21.14.2 PRODUCT PORTFOLIO 778
  • 21.14.3 RECENT DEVELOPMENTS 780
• 21.15 CHEMBIO DIAGNOSTIC SYSTEMS, INC. 780
  • 21.15.1 COMPANY SNAPSHOT 780
  • 21.15.2 REVENUE ANALYSIS 781
  • 21.15.3 PRODUCT PORTFOLIO 782
  • 21.15.4 RECENT DEVELOPMENTS 782
• 21.16 DIASORIN S.P.A. 783
  • 21.16.1 COMPANY SNAPSHOT 783
  • 21.16.2 REVENUE ANALYSIS 783
  • 21.16.3 PRODUCT PORTFOLIO 784
  • 21.16.4 PRODUCT PORTFOLIO (DIASORIN MOLECULAR LLC, A SUBSIDIARY OF DIASORIN S.P.A.) 785
  • 21.16.5 RECENT DEVELOPMENTS 786
• 21.17 EKF DIAGNOSTICS HOLDINGS PLC 787
  • 21.17.1 COMPANY SNAPSHOT 787
  • 21.17.2 REVENUE ANALYSIS 788
  • 21.17.3 PRODUCT PORTFOLIO 788
  • 21.17.4 RECENT DEVELOPMENTS 789
• 21.18 GERMAINE LABORATORIES, INC. 790
  • 21.18.1 COMPANY SNAPSHOT 790
  • 21.18.2 PRODUCT PORTFOLIO 790
  • 21.18.3 RECENT DEVELOPMENT 792
• 21.19 QIAGEN 793
  • 21.19.1 COMPANY SNAPSHOT 793
  • 21.19.2 REVENUE ANALYSIS 793
  • 21.19.3 PRODUCT PORTFOLIO 794
  • 21.19.4 RECENT DEVELOPMENTS 794

 

• 21.20 GRIFOLS, S.A. 795
  • 21.20.1 COMPANY SNAPSHOT 795
  • 21.20.2 REVENUE ANALYSIS 795
  • 21.20.3 PRODUCT PORTFOLIO 796
  • 21.20.4 RECENT DEVELOPMENTS 797
• 21.21 QUIDEL CORPORATION 798
  • 21.21.1 COMPANY SNAPSHOT 798
  • 21.21.2 REVENUE ANALYSIS 798
  • 21.21.3 PRODUCT PORTFOLIO 799
  • 21.21.4 RECENT DEVELOPMENTS 800
• 21.22 HEMOSURE, INC. 801
  • 21.22.1 COMPANY SNAPSHOT 801
  • 21.22.2 PRODUCT PORTFOLIO 801
  • 21.22.3 RECENT DEVELOPMENT 801
• 21.23 HUMASIS 802
  • 21.23.1 COMPANY SNAPSHOT 802
  • 21.23.2 PRODUCT PORTFOLIO 802
  • 21.23.3 RECENT DEVELOPMENT 802
• 21.24 ILLUMINA, INC. 803
  • 21.24.1 COMPANY SNAPSHOT 803
  • 21.24.2 REVENUE ANALYSIS 803
  • 21.24.3 PRODUCT PORTFOLIO 804
  • 21.24.4 RECENT DEVELOPMENTS 804
• 21.25 LAMDAGEN CORPORATION 806
  • 21.25.1 COMPANY SNAPSHOT 806
  • 21.25.2 PRODUCT PORTFOLIO 806
  • 21.25.3 RECENT DEVELOPMENTS 806
• 21.26 LIFESIGN LLC. 807
  • 21.26.1 COMPANY SNAPSHOT 807
  • 21.26.2 PRODUCT PORTFOLIO 807
  • 21.26.3 RECENT DEVELOPMENT 807
• 21.27 MEDIXBIOCHEMICA 808
  • 21.27.1 COMPANY SNAPSHOT 808
  • 21.27.2 PRODUCT PORTFOLIO 808
  • 21.27.3 RECENT DEVELOPMENTS 809
• 21.28 MICROGEN DIAGNOSTICS 810
  • 21.28.1 COMPANY SNAPSHOT 810
  • 21.28.2 SERVICE PORTFOLIO 810
  • 21.28.3 RECENT DEVELOPMENT 810

 

• 21.29 NANOENTEK 811
  • 21.29.1 COMPANY SNAPSHOT 811
  • 21.29.2 PRODUCT PORTFOLIO 811
  • 21.29.3 RECENT DEVELOPMENT 812
• 21.30 NOVA BIOMEDICAL 813
  • 21.30.1 COMPANY SNAPSHOT 813
  • 21.30.2 PRODUCT PORTFOLIO 813
  • 21.30.3 RECENT DEVELOPMENTS 814
• 21.31 ORTHO CLINICAL DIAGNOSTICS 815
  • 21.31.1 COMPANY SNAPSHOT 815
  • 21.31.2 PRODUCT PORTFOLIO 815
  • 21.31.3 RECENT DEVELOPMENT 815
• 21.32 PERKINELMER INC. 816
  • 21.32.1 COMPANY SNAPSHOT 816
  • 21.32.2 REVENUE ANALYSIS 816
  • 21.32.3 PRODUCT PORTFOLIO 817
  • 21.32.4 RECENT DEVELOPMENT 817
• 21.33 SANNUO BIOSENSOR LTD. 818
  • 21.33.1 COMPANY SNAPSHOT 818
  • 21.33.2 PRODUCT PORTFOLIO 818
  • 21.33.3 RECENT DEVELOPMENTS 819
• 21.34 STRECK 820
  • 21.34.1 COMPANY SNAPSHOT 820
  • 21.34.2 PRODUCT PORTFOLIO 820
  • 21.34.3 RECENT DEVELOPMENTS 821
• 21.35 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION) 822
  • 21.35.1 COMPANY SNAPSHOT 822
  • 21.35.2 REVENUE ANALYSIS 822
  • 21.35.3 PRODUCT PORTFOLIO 823
  • 21.35.4 RECENT DEVELOPMENT 823

22 QUESTIONNAIRE 824

23 RELATED REPORTS 829

LIST OF FIGURES

LIST OF FIGURES

• FIGURE 1 GLOBAL DIAGNOSTIC TESTS MARKET : SEGMENTATION 95
• FIGURE 2 GLOBAL DIAGNOSTIC TESTS MARKET : DATA TRIANGULATION 99
• FIGURE 3 GLOBAL DIAGNOSTIC TESTS MARKET : DROC ANALYSIS 100
• FIGURE 4 GLOBAL DIAGNOSTIC TESTS MARKET : COUNTRY VS REGIONAL MARKET ANALYSIS 101
• FIGURE 5 GLOBAL DIAGNOSTIC TESTS MARKET : COMPANY RESEARCH ANALYSIS 101
• FIGURE 6 GLOBAL DIAGNOSTIC TESTS MARKET : INTERVIEW DEMOGRAPHICS 103
• FIGURE 7 GLOBAL DIAGNOSTIC TESTS MARKET: DBMR MARKET POSITION GRID 104
• FIGURE 8 GLOBAL DIAGNOSTIC TESTS MARKET: VENDOR SHARE ANALYSIS 105
• FIGURE 9 GLOBAL DIAGNOSTIC TESTS MARKET : SEGMENTATION 109
• FIGURE 10 INCREASING PREVALENCE OF CHRONIC DISEASE, RISING NUMBER OF IVD TESTS CONDUCTED ACROSS THE GLOBE, ADEQUATE REIMBURSEMENT POLICIES, IMPROVING DIAGNOSIS SEEKING RATE ACROSS THE GLOBE, EXTENDING REACH OF MOLECULAR DIAGNOSTIC ARE EXPECTED TO THE DRIVE THE DIAGNOSTIC TESTS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 110
• FIGURE 11 SERVICE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE DIAGNOSTIC TESTS MARKET IN 2020 & 2027 110
• FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL DIAGNOSTIC TESTS MARKET 112
• FIGURE 13 EPIDEMIOLOGY OF CHRONIC CONDITIONS, WITH TIME (1990-2015) 113
• FIGURE 14 EUROPEAN IVD MARKET REVENUE (USD MILLION) 114
• FIGURE 15 TOTAL EXPORT OF THE U.S. IVD INDUSTRY (IN MILLION) 115
• FIGURE 16 DEMAND SUPPLY GAP OF HEALTHCARE PROFESSIONALS 120
• FIGURE 17 GLOBAL DIAGNOSTIC TESTS MARKET: BY TYPE, 2019 129
• FIGURE 18 GLOBAL DIAGNOSTIC TESTS MARKET: BY TYPE, 2019-2027 (USD MILLION) 130
• FIGURE 19 GLOBAL DIAGNOSTIC TESTS MARKET: BY TYPE, CAGR (2020-2027) 131
• FIGURE 20 GLOBAL DIAGNOSTIC TESTS MARKET: BY TYPE, LIFELINE CURVE 131
• FIGURE 21 GLOBAL DIAGNOSTIC TESTS MARKET: BY SOLUTION, 2019 150
• FIGURE 22 GLOBAL DIAGNOSTIC TESTS MARKET: BY SOLUTION, 2019-2027 (USD MILLION) 151
• FIGURE 23 GLOBAL DIAGNOSTIC TESTS MARKET: BY SOLUTION, CAGR (2020-2027) 151
• FIGURE 24 GLOBAL DIAGNOSTIC TESTS MARKET: BY SOLUTION, LIFELINE CURVE 152
• FIGURE 25 GLOBAL DIAGNOSTIC TESTS MARKET: BY TECHNOLOGY, 2019 163
• FIGURE 26 GLOBAL DIAGNOSTIC TESTS MARKET: BY TECHNOLOGY, 2019-2027 (USD MILLION) 164
• FIGURE 27 GLOBAL DIAGNOSTIC TESTS MARKET: BY TECHNOLOGY, CAGR (2020-2027) 164
• FIGURE 28 GLOBAL DIAGNOSTIC TESTS MARKET: BY TECHNOLOGY, LIFELINE CURVE 165
• FIGURE 29 GLOBAL DIAGNOSTIC TESTS MARKET: BY EN MODE OF TESTING D USER, 2019 175
• FIGURE 30 GLOBAL DIAGNOSTIC TESTS MARKET: BY MODE OF TESTING, 2019-2027 (USD MILLION) 176
• FIGURE 31 GLOBAL DIAGNOSTIC TESTS MARKET: BY MODE OF TESTING, CAGR (2020-2027) 176
• FIGURE 32 GLOBAL DIAGNOSTIC TESTS MARKET: BY MODE OF TESTING, LIFELINE CURVE 177
• FIGURE 33 GLOBAL DIAGNOSTIC TESTS MARKET: BY APPROACH, 2019 181
• FIGURE 34 GLOBAL DIAGNOSTIC TESTS MARKET: BY APPROACH, 2019-2027 (USD MILLION) 182
• FIGURE 35 GLOBAL DIAGNOSTIC TESTS MARKET: BY APPROACH, CAGR (2020-2027) 182
• FIGURE 36 GLOBAL DIAGNOSTIC TESTS MARKET: BY APPROACH, LIFELINE CURVE 183
• FIGURE 37 GLOBAL DIAGNOSTIC TESTS MARKET: BY SAMPLE TYPE, 2019 187
• FIGURE 38 GLOBAL DIAGNOSTIC TESTS MARKET: BY SAMPLE TYPE, 2019-2027 (USD MILLION) 188
• FIGURE 39 GLOBAL DIAGNOSTIC TESTS MARKET: BY SAMPLE TYPE, CAGR (2020-2027) 188
• FIGURE 40 GLOBAL DIAGNOSTIC TESTS MARKET: BY SAMPLE TYPE, LIFELINE CURVE 189
• FIGURE 41 GLOBAL DIAGNOSTIC TESTS MARKET: BY APPLICATION, 2019 195
• FIGURE 42 GLOBAL DIAGNOSTIC TESTS MARKET: BY APPLICATION, 2019-2027 (USD MILLION) 196
• FIGURE 43 GLOBAL DIAGNOSTIC TESTS MARKET: BY APPLICATION, CAGR (2020-2027) 196
• FIGURE 44 GLOBAL DIAGNOSTIC TESTS MARKET: BY APPLICATION, LIFELINE CURVE 197
• FIGURE 45 GLOBAL DIAGNOSTIC TESTS MARKET: BY TESTING TYPE, 2019 209
• FIGURE 46 GLOBAL DIAGNOSTIC TESTS MARKET: BY TESTING TYPE, 2019-2027 (USD MILLION) 210
• FIGURE 47 GLOBAL DIAGNOSTIC TESTS MARKET: BY TESTING TYPE, CAGR (2020-2027) 210
• FIGURE 48 GLOBAL DIAGNOSTIC TESTS MARKET: BY TESTING TYPE, LIFELINE CURVE 211
• FIGURE 49 GLOBAL DIAGNOSTIC TESTS MARKET: BY AGE, 2019 216
• FIGURE 50 GLOBAL DIAGNOSTIC TESTS MARKET: BY AGE, 2019-2027 (USD MILLION) 217
• FIGURE 51 GLOBAL DIAGNOSTIC TESTS MARKET: BY AGE, CAGR (2020-2027) 217
• FIGURE 52 GLOBAL DIAGNOSTIC TESTS MARKET: BY AGE, LIFELINE CURVE 218
• FIGURE 53 GLOBAL DIAGNOSTIC TESTS MARKET: BY END USER, 2019 222
• FIGURE 54 GLOBAL DIAGNOSTIC TESTS MARKET: BY END USER, 2019-2027 (USD MILLION) 223
• FIGURE 55 GLOBAL DIAGNOSTIC TESTS MARKET: BY END USER, CAGR (2020-2027) 223
• FIGURE 56 GLOBAL DIAGNOSTIC TESTS MARKET: BY END USER, LIFELINE CURVE 224
• FIGURE 57 GLOBAL DIAGNOSTIC TESTS MARKET: BY DISTRIBUTION CHANNEL, 2019 232
• FIGURE 58 GLOBAL DIAGNOSTIC TESTS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION) 233
• FIGURE 59 GLOBAL DIAGNOSTIC TESTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 233
• FIGURE 60 GLOBAL DIAGNOSTIC TESTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 234
• FIGURE 61 GLOBAL DIAGNOSTIC TESTS MARKET: SNAPSHOT (2019) 237
• FIGURE 62 GLOBAL DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019) 239
• FIGURE 63 GLOBAL DIAGNOSTIC TESTS MARKET: BY COUNTRY (2020 & 2027) 239
• FIGURE 64 GLOBAL DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019 & 2027) 240
• FIGURE 65 GLOBAL DIAGNOSTIC TESTS MARKET: BY PRODUCT (2020-2027) 240
• FIGURE 66 NORTH AMERICA DIAGNOSTIC TESTS MARKET: SNAPSHOT (2019) 241
• FIGURE 67 NORTH AMERICA DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019) 244
• FIGURE 68 NORTH AMERICA DIAGNOSTIC TESTS MARKET: BY COUNTRY (2020 & 2027) 244
• FIGURE 69 NORTH AMERICA DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019 & 2027) 245
• FIGURE 70 NORTH AMERICA DIAGNOSTIC TESTS MARKET: BY PRODUCT (2020-2027) 245
• FIGURE 71 EUROPE DIAGNOSTIC TESTS MARKET: SNAPSHOT (2019) 290
• FIGURE 72 EUROPE DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019) 292
• FIGURE 73 EUROPE DIAGNOSTIC TESTS MARKET: BY COUNTRY (2020 & 2027) 292
• FIGURE 74 EUROPE DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019 & 2027) 293
• FIGURE 75 EUROPE DIAGNOSTIC TESTS MARKET: BY PRODUCT (2020-2027) 293
• FIGURE 76 ASIA-PACIFIC DIAGNOSTIC TESTS MARKET: SNAPSHOT (2019) 472
• FIGURE 77 ASIA-PACIFIC DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019) 474
• FIGURE 78 ASIA-PACIFIC DIAGNOSTIC TESTS MARKET: BY COUNTRY (2020 & 2027) 474
• FIGURE 79 ASIA-PACIFIC DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019 & 2027) 475
• FIGURE 80 ASIA-PACIFIC DIAGNOSTIC TESTS MARKET: BY PRODUCT (2020-2027) 475
• FIGURE 81 SOUTH AMERICA DIAGNOSTIC TESTS MARKET: SNAPSHOT (2019) 610
• FIGURE 82 SOUTH AMERICA DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019) 612
• FIGURE 83 SOUTH AMERICA DIAGNOSTIC TESTS MARKET: BY COUNTRY (2020 & 2027) 612
• FIGURE 84 SOUTH AMERICA DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019 & 2027) 613
• FIGURE 85 SOUTH AMERICA DIAGNOSTIC TESTS MARKET: BY PRODUCT (2020-2027) 613
• FIGURE 86 MIDDLE EAST AND AFRICA DIAGNOSTIC TESTS MARKET: SNAPSHOT (2019) 659
• FIGURE 87 MIDDLE EAST AND AFRICA DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019) 661
• FIGURE 88 MIDDLE EAST AND AFRICA DIAGNOSTIC TESTS MARKET: BY COUNTRY (2020 & 2027) 661
• FIGURE 89 MIDDLE EAST AND AFRICA DIAGNOSTIC TESTS MARKET: BY COUNTRY (2019 & 2027) 662
• FIGURE 90 MIDDLE EAST AND AFRICA DIAGNOSTIC TESTS MARKET: BY PRODUCT (2020-2027) 662
• FIGURE 91 GLOBAL DIAGNOSTIC TESTS MARKET: COMPANY SHARE 2019 (%) 741
• FIGURE 92 NORTH AMERICA DIAGNOSTIC TESTS MARKET: COMPANY SHARE 2019 (%) 742
• FIGURE 93 EUROPE DIAGNOSTIC TESTS MARKET: COMPANY SHARE 2019 (%) 743
• FIGURE 94 ASIA-PACIFIC DIAGNOSTIC TESTS MARKET: COMPANY SHARE 2019 (%) 744